Mikkael A. Sekeres, MD, on MDS, CMML, or AML: Pevonedistat and Azacitidine

June 10, 2020 By The ASCO Post Staff

Mikkael A. Sekeres, MD, of the Cleveland Clinic, discusses data from a phase II study of pevonedistat plus azacitidine vs azacitidine alone in patients with higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or low-blast acute myeloid leukemia (Abstract 7506).

Related Content